It is estimated that about half of the world’s vaccinations are wasted because of exposure to high temperatures.
A Bath biotechnology company is on course to revolutionise the delivery of life-saving vaccines in the developing world by getting rid of the need for costly refrigeration.
The new Stablevax technology developed by Queen Square-based Stablepharma involves a groundbreaking technique for drying and stabilising vaccines inside a disposable syringe which can be stored at any temperature and rehydrated for immediate injection.
The Stablevax syringe eliminates the need for an expensive and often ineffective “cold chain” of refrigerators to store and transport vaccines.
It is estimated that about half of the world’s vaccinations are wasted because of exposure to high temperatures.
Stablevax has been developed by the firm’s chief scientific officer Dr Bruce Roser, who is a world authority on drug stabilisation and delivery and who has published more than 100 scientific papers.
The company is now seeking investment of £200,000 to pay for medical certification of the new vaccine delivery product.
Stablepharma managing director Nick Child said: “This technology represents a major breakthrough in the delivery of vaccines to the developing world.
via SouthWestBusiness
The Latest Streaming News: Vaccines updated minute-by-minute
Bookmark this page and come back often
Latest NEWS
Latest VIDEO